River Road Asset Management LLC Purchases 46,289 Shares of Enovis Corporation $ENOV

River Road Asset Management LLC grew its holdings in shares of Enovis Corporation (NYSE:ENOV) by 3.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,487,277 shares of the company’s stock after acquiring an additional 46,289 shares during the period. River Road Asset Management LLC owned 2.60% of Enovis worth $39,621,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Arax Advisory Partners acquired a new position in shares of Enovis in the 4th quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its stake in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. GAMMA Investing LLC grew its stake in Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after purchasing an additional 1,446 shares during the period. Danske Bank A S bought a new stake in Enovis in the third quarter worth approximately $64,000. Finally, iSAM Funds UK Ltd bought a new stake in Enovis in the third quarter worth approximately $80,000. 98.45% of the stock is owned by institutional investors.

Insider Activity

In other Enovis news, insider Oliver Engert purchased 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average price of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders acquired 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ENOV shares. Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Zacks Research lowered shares of Enovis from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 1st. Evercore reiterated an “outperform” rating and set a $36.00 target price on shares of Enovis in a research report on Friday, May 8th. William Blair assumed coverage on shares of Enovis in a research note on Friday, April 17th. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company reduced their price target on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $44.50.

Enovis Stock Up 5.3%

ENOV stock opened at $21.95 on Friday. The stock’s 50 day simple moving average is $23.93 and its 200 day simple moving average is $24.32. The company has a market cap of $1.26 billion, a P/E ratio of -1.10 and a beta of 1.38. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. Enovis Corporation has a fifty-two week low of $20.55 and a fifty-two week high of $36.82.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts expect that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.